Description
This CNV is a 42.5 Mb duplication of Xq21.1q24 on chromosome X, (seq[GRCh37]dup(X)(q21.1q24); chrX:g.76794355_119282836dup). The CNV constitutes a duplication encompassing 178 protein coding genes, including the PLP1 gene, which is associated with Pelizaeus-Merzbzcher disease (PMD) and is the only gene in the duplication currently reported with triplosensitivity. The centromeric breakpoint of this CNV is within the ATRX gene, which is associated with alpha-thalassemia X-linked intellectual disability syndrome; however, carrier females rarely show clinical manifestations and have skewed X inactivation (Stevenson, 2000). At least ten affected female individuals with similar chromosome X duplications have been reported in literature, including at least six who carried the variant in a de novo state (Carrozzo et al. 1997; Tachdjian et al. 2004; Firth et al. 2009; Carvalho et al. 2012; Jin et al. 2015; Parissone et al. 2020). Common features of PMD includes hypomyelination, nystagmus, ataxia, developmental delay, and spastic quadriplegia (Wolf et al. 1999). Female probands carrying similar duplications exhibit variable phenotypes compared to males, ranging from mild to severe, and include global developmental delay, gonadal dysgenesis, intrauterine growth restriction, failure to thrive, feeding difficulties, behavioral abnormalities, skeletal anomalies, short stature, low weight, dysmorphic features, seizures, wide spaced nipples, high arched palate, brachydactyly, clinodactyly, and hearing loss (Carrozzo et al. 1997; Tachdjian et al. 2004; Carvalho et al. 2012; Parissone et al. 2020). This CNV has not been reported in controls. Based on the available evidence, this CNV is classified as pathogenic.
| # | Sample | Method | Observation |
|---|
| Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences |
|---|
| 1 | unknown | unknown | not provided | not provided | not provided | | not provided | not provided | not provided | not provided |
